Prostate Cancer Diagnostics Market Report 2026

The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $5.02 billion in 2025 to $5.66 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to rising prevalence of prostate cancer, expansion of clinical diagnostic infrastructure, increased use of PSA and biopsy testing, availability of imaging-based diagnostic tools, growing awareness of early cancer detection.

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $9.19 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancement of molecular and genomic diagnostics, rising adoption of precision oncology approaches, expansion of population screening initiatives, increasing investments in diagnostic automation, growing demand for personalized cancer diagnostics. Major trends in the forecast period include increasing adoption of advanced diagnostic assays, rising use of biomarker-based prostate cancer testing, growing integration of AI-assisted imaging analysis, expansion of early detection screening programs, enhanced focus on diagnostic accuracy and risk stratification.

The rising prevalence of prostate cancer is expected to drive the growth of the prostate cancer diagnostics market in the coming years. Prostate cancer develops in the prostate gland, which is part of the male reproductive system. Prostate cancer diagnostics enable early identification of the disease through a range of testing methods, including prostate-specific antigen (PSA) testing and advanced imaging technologies. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit organization focused on cancer prevention and research, an estimated 288,300 new cases of prostate cancer and 34,700 prostate cancer-related deaths were reported in 2023. Therefore, the increasing incidence of prostate cancer is fueling the expansion of the prostate cancer diagnostics market.

Major companies operating in the prostate cancer diagnostics market are concentrating on the development of advanced artificial intelligence-powered solutions to enhance diagnostic accuracy, shorten interpretation timelines, and support earlier detection of prostate cancer. AI-based diagnostic tools use machine learning algorithms to identify regions of prostatic adenocarcinoma and analyze whole-slide images from prostate core needle biopsies, helping pathologists deliver faster and more precise diagnoses. For instance, in March 2023, Qritive, a Singapore-based diagnostic technology company, launched QAi Prostate, an AI-driven prostate cancer diagnostic solution designed for pathologists. This platform streamlines workflows, improves diagnostic precision, and reduces the time required for clinical decision-making.

In October 2024, Trinity Biotech plc, an Ireland-based provider of in vitro diagnostics and diabetes management diagnostic products, acquired EpiCapture Limited for an undisclosed amount. Through this acquisition, Trinity Biotech sought to expand into the oncology diagnostics space by adding a non-invasive, epigenetic prostate cancer monitoring test to its product portfolio. EpiCapture Limited is an Ireland-based company that develops a urine-based epigenetic DNA methylation test for evaluating the risk of aggressive prostate cancer.

Major companies operating in the prostate cancer diagnostics market are F Hoffmann La Roche AG, Bayer AG, Thermo Fisher Scientific Inc, Abbott Laboratories Inc, Siemens Healthineers AG, Becton Dickinson And Company, Agilent Technologies Inc, Hologic Inc, bioMerieux SA, Beckman Coulter Inc, Qiagen NV, Exact Sciences Corporation, DiaSorin SpA, OPKO Health Inc, Myriad Genetics Inc, Cepheid Inc, NeoGenomics Laboratories Inc, Fujirebio Diagnostics Inc, Ambry Genetics Corporation, MDxHealth SA, Exosome Diagnostics Inc, Cellanyx Diagnostics Inc, A3P Biomedical AB, Roche Diagnostics GmbH, Sysmex Corporation.

North America was the largest region in the prostate cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the prostate cancer diagnostics market by increasing costs of imported imaging systems, diagnostic reagents, biopsy instruments, and laboratory consumables used across preliminary and confirmatory testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported diagnostic equipment, while Asia-Pacific faces higher costs in reagent sourcing and instrument manufacturing. These tariffs raise testing costs and slow technology upgrades in diagnostic facilities. However, they are also encouraging local production of diagnostic reagents, regional manufacturing of instruments, and investment in domestic diagnostic innovation ecosystems.

The prostate cancer diagnostics market research report is one of a series of new reports that provides prostate cancer diagnostics market statistics, including prostate cancer diagnostics industry global market size, regional shares, competitors with a prostate cancer diagnostics market share, detailed prostate cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. This prostate cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prostate cancer diagnostics involve the identification and confirmation of prostate cancer through diagnostic tests and clinical evaluations to assess the presence, stage, and severity of the disease and to guide treatment decisions. These diagnostics are commonly used for conditions such as prostatic adenocarcinoma, transitional cell carcinoma, and neuroendocrine tumors.

The primary products used in prostate cancer diagnostics include instruments, reagents and consumables, and accessories. Accessories include items that are not always essential but can be used alongside diagnostic tools to improve effectiveness, such as prostate-specific antigen (PSA) test kits, biopsy needles, and ultrasound gel used in prostate cancer detection. The different test types include preliminary and confirmatory tests that diagnose various forms of prostate cancer, including squamous cell carcinoma, small cell carcinoma, transitional cell carcinoma, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, and acinar adenocarcinoma. These diagnostics are utilized across peer groups such as adults, pediatric patients, and geriatrics, and are performed by end users including hospitals, independent diagnostic laboratories, cancer research institutes, and others.

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.